Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
The purpose of this study is to evaluate the effectiveness of insulin delivered in the
 peritoneum (abdomen)by an implantable pump in Type 1 diabetics.
Implantable insulin delivery pumps have been shown to reduce the occurrence of severe
 hypoglycemia in Type 1 DM subjects, as demonstrated in numerous European studies. Glycemic
 control is difficult to attain in subjects using exogenous insulin due to the risk of severe
 hypoglycemia. This study is aimed at comparing the efficacy of intraperitoneal (IP) insulin
 therapy to intensive subcutaneous insulin therapy over a period of 12 months.
-  Type 1 diabetes mellitus (American Diabetes Association definition)

 -  HbA1c greater than or equal to 7.5%

 -  Intensive insulin treatment for at least 3 months

 -  Physical and intellectual ability to operate MIP system

 -  Subject has been under the routine care of the investigator for at least two months
 prior to enrollment

 -  Subject has a reliable support person (defined as a person who has daily contact with
 the subject and knows whom to contact in the event of an emergency).

 -  Capability and willingness to perform self-monitoring of blood glucose at least four
 times daily for 9 months of the study and 7 times daily for 3 months of the study

 -  Physical and intellectual ability to operate the MIP system and to comply with the
 data reporting requirements of the study.

 -  Subject is willing to sign the informed consent form (approved by local Institutional
 Review Board and Medtronic MiniMed)

 Exclusion Criteria:

 -  The subject's insulin usage exceeds 66 units per day.

 -  Severe complications such as advanced autonomic neuropathy, legal blindness, or
 symptomatic cardiovascular disease as evidenced by a cardiovascular episode within the
 last six months

 -  Reside at or plan to travel to elevations above 8000 feet during the study period
 (commercial airline travel is acceptable)

 -  Subject who is pregnant, of childbearing potential or lactating and is neither
 surgically sterile, using contraceptives (devices, oral or implanted) nor other
 physician approved contraceptive

 -  The subject has any major concomitant disease or any physical or psychological
 disorder within the last five years, which might be considered life threatening, or
 which might confound the collection or interpretation of the study data

 -  The subject has previously enrolled in or participated in an investigational drug or
 device study within the preceding 4 weeks

 -  The subject has any condition that precludes him/her from completing the study
 requirements

 -  Has plans for activities which require them to go 25 feet below sea level